Comment on the research of accurate prevention and treatment of myelodysplastic syndrome with Traditional Chinese Medicine

Jiahui LU

doi:10.3969/j.issn.1006-2157.2022.03.001

您当前的位置：

首页 >

文章列表页 >

Comment on the research of accurate prevention and treatment of myelodysplastic syndrome with Traditional Chinese Medicine

Expert Commentary | 更新时间：2022-04-01

- Comment on the research of accurate prevention and treatment of myelodysplastic syndrome with Traditional Chinese Medicine
- Journal of Beijing University of Traditional Chinese Medicine Vol. 45, Issue 3, Pages: 217-222(2022)
- 作者机构：
  
  上海中医药大学附属市中医医院　上海　200071
- 作者简介：
- 基金信息：
  
  National Natural Science Foundation of China(81873286);Program of Shanghai Academic Research Leader(20XD1403500);Training Plan for Excellent Discipline Leaders of Municipal Health and Family Planning System(2018BR15);Special Major Project of Medical Innovation Research of Shanghai Science and Technology Commission(21Y31920400);Clinical Science and Technology Innovation Project of Shanghai Shenkang Hospital Development Center(SHDC12020128)
- DOI：10.3969/j.issn.1006-2157.2022.03.001
  CLC： R246.5
- Received：06 August 2021，
  
  Published：30 March 2022
- 稿件说明：
移动端阅览
Jiahui LU. Comment on the research of accurate prevention and treatment of myelodysplastic syndrome with Traditional Chinese Medicine[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(3): 217-222.
DOI：

Jiahui LU. Comment on the research of accurate prevention and treatment of myelodysplastic syndrome with Traditional Chinese Medicine[J]. Journal of Beijing University of Traditional Chinese Medicine, 2022, 45(3): 217-222. DOI： 10.3969/j.issn.1006-2157.2022.03.001.

摘要

回顾分析当前中医药防治骨髓增生异常综合征(MDS)研究现状，并通过长期临床实践，提出“虚毒并治”理论下的MDS中医药防治模式，主要内容包括：根据不同治疗反应和转化风险进行分层防治——通过整体、动态、连续地防治MDS发生、发展、治疗及转归全过程；监测导致MDS的前驱疾病，包括意义未明的特发性血细胞减少症、意义未明的克隆性血细胞减少症等，以刺激造血为治疗目标，治以补虚为主、兼以解毒，以抑制克隆、阻止或延缓向MDS进展；治疗较低危MDS，以抑制克隆与刺激造血并重，治以补虚解毒，以提升血象和提高临床缓解率；控制较高危MDS，以抑制克隆为治疗目标，治以解毒为主、兼以补虚，以延长向白血病转化和复发耐药时间；在“扶正祛邪、攻补守衡”聚焦主病、主证基础上，注重“固本祛邪”全病程管理，积极预防和治疗相关并发症，提高临床疗效与生存质量，恢复机体功能状态，降低治疗成本，使更多的患者获益。同时提出，现有中医药治疗和能体现中西医协同优势的临床文献级别有限，亟待多中心、大样本、严格随机对照、高质量的临床研究，获得更多高质量循证医学证据。

Abstract

The current status of research on the prevention and treatment of myelodysplastic syndrome (MDS) withTraditional Chinese Medicine (TCM) was reviewed and analyzed

and through long-term clinical practice

aprecise TCM-based prevention and treatment strategy based on the theory of combination of deficiency and toxin was proposed. The main contents included: (i) precise layered prevention and treatment according to different treatment reactions and conversion risks

through the overall

dynamic

continuous

and accurate prevention and treatment of MDS

affecting the whole process of its occurrence

development

treatment

and outcome; and (ii) to monitor the prodromal diseases pre-MDS

includingIdiopathic cytopenia of undetermined significance (ICUS)andClonal cytopenia of undetermined significance (CCUS)

which cause MDS

with the stimulation of hematopoiesis as the treatment target and the treatment is mainly based on tonifying deficiency

accompanied by detoxification

in order to inhibit cloning and prevent or delay the progression to MDS; and (iii) treating lower-risk MDS

emphasis is placed on inhibition of cloning and stimulation of hematopoiesis

while treating tonifying deficiency and detoxicating

thereby improving routine blood test values and the clinical remission rate; and (iv) controlling higher-risk MDS

inhibition of cloning is applied as the treatment strategy

in combination with detoxification as the main therapy and tonifying deficiency at the same time to prolong the time of transformation to leukemia and relapse drug resistance. Based on the focus on the main disease and the main goal of "strengthening the body resistance to eliminate pathogenic factors

attacking

supplementing

and maintaining balance

" the whole course management of "consolidating the root and eliminating pathogenic factors" was emphasized

relevant complications were actively prevented and treated

clinical efficacy and quality of life were improved

body function was restored

and treatment costs were reduced

so that more patients could benefit. At the same time

it was pointed out that the existing clinical literature concerning precision treatment with TCM that could reflect the synergistic advantages of TCM and Western medicine was limited in scope

and there is an urgent need for clinical research that is multi-centered

large in sample size

strictly randomized controlled

and of high quality to develop more high-quality evidence-based medicine.

关键词

Keywords

references

中华医学会血液学分会 . 骨髓增生异常综合征中国诊断与治疗指南(2019年版) [J]. 中华血液学杂志， 2019 ， 40 ( 2 )： 89 － 97 .

CAZZOLA M . MyelodysplasticSyndromes [J]. N Engl J Med ， 2020 ， 383 ( 14 )： 1358 － 1374 .

FENAUX P , HAASE D , SANTINI V , et al . Myelodysplastic syndromes: ESMO clinical practice guidelines for diagnosis, treatment and follow-up(dagger) [J]. Ann Oncol ， 2021 ， 32 ( 2 )： 142 － 156 .

王蔚 . 成人骨髓增生异常综合征和再生障碍性贫血的发病率和预后研究 [D]. 上海：复旦大学， 2010 .

BENNETT J M , CATOVSKY D , DANIEL M T , et al . Proposals for the classification of the myelodysplastic syndromes [J]. Br J Haematol ， 1982 ， 51 ( 2 )： 189 － 199 .

HAMILTON-PATERSON J L . Pre-leukaemicanaemia [J]. ActaHaematol ， 1949 ， 2 ( 5 )： 309 － 316 .

BENNETT J M , CATOVSKY D , DANIEL M T , et al . Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group [J]. Br J Haematol ， 1976 ， 33 ( 4 )： 451 － 458 .

TANAKA T N , BEJAR R . MDS overlap disorders and diagnostic boundaries [J]. Blood ， 2019 ， 133 ( 10 )： 1086 － 1095 .

PLATZBECKER U , KUBASCH A S , HOMER-BOUTHIETTE C , et al . Current challenges and unmet medical needs in myelodysplastic syndromes [J]. Leukemia ， 2021 ， 35 ( 8 )： 2182 － 2198 .

BERSANELLI M , TRAVAGLINO E , MEGGENDORFER M , et al . Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplasticsyndromes [J]. J Clin Oncol ， 2021 ， 39 ( 11 )： 1223 － 1233 .

CHANIAS I , STOJKOV K , STEHLE G T , et al . Myelodysplasticsyndromes in the postgenomicera and future perspectives for precision medicine [J/OL]. Cancers (Basel) ， 2021 ， 13 ( 13 )： 3296 [ 2021-07-31 ]. https：//www.mdpi.com/2072－6694/13/13/3296 https：//www.mdpi.com/2072－6694/13/13/3296 .

刘蕊，许兰平 . 骨髓增生异常综合征的造血干细胞移植治疗现状和进展 [J]. 临床血液学杂志， 2017 ， 30 ( 11 )： 891 － 895 .

VALENT P . ICUS, IDUS, CHIP and CCUS: Diagnostic criteria, separation from MDS and clinical implications [J]. Pathobiology ， 2019 ， 86 ( 1 )： 30 － 38 .

JOFFE E , GREENBAUM U , MAN-EL G , et al . Kinetics of pre-myelodysplastic syndromes blood values correlate with disease risk and survival [J]. Hematol Oncol ， 2020 ， 38 ( 5 )： 782 － 791 .

AL-KALI A , ZBLEWSKI D , FORAN J M , et al . Outcome of myelodysplasticsyndromes over time in the United States: A national cancer data base study from 2004—2013 [J]. Mayo Clin Proc ， 2019 ， 94 ( 8 )： 1467 － 1474 .

陈信义，李冬云 . 中医药防治骨髓增生异常综合征的研究现状与展望 [J]. 北京中医药大学学报， 1996 ， 19 ( 2 )： 8 － 12 .

李冬云 . 中医药治疗骨髓增生异常综合征临床研究进展 [J]. 医学综述， 1996 ( 8 )： 425 － 430 .

陈信义，麻柔，李冬云 . 规范常见血液病中医病名建议 [J]. 中国中西医结合杂志， 2009 ， 29 ( 11 )： 1040 － 1041 .

王敬毅，徐瑞荣，周延峰 . 中西医结合治疗骨髓增生异常综合征专家共识 [J]. 中华中医药杂志， 2013 ， 28 ( 1 )： 38 － 40 .

中国中西医结合学会血液学专业委员会骨髓增生异常综合征专家委员会．骨髓增生异常综合征中西医结合诊疗专家共识(2018年) [J]. 中国中西医结合杂志， 2018 ， 38 ( 8 )： 914 － 920 .

世界中医药学会联合会血液病专业技术标准审定委员会．髓毒劳(骨髓增生异常综合征)中医临床实践指南 [J]. 国际中医中药杂志， 2019 ， 41 ( 4 )： 323 － 326 .

申小惠，孙伟玲，鲍计章，等 . 健脾补肾解毒方治疗骨髓增生异常综合征临床观察 [J]. 上海中医药大学学报， 2012 ， 26 ( 5 )： 34 － 37 .

夏小军，段赟，郭炳涛，等 . 回生胶囊联合环孢素软胶囊与沙利度胺治疗中危组骨髓增生异常综合征临床研究 [J]. 新中医， 2020 ， 52 ( 22 )： 108 － 112 .

段连风，李君，王茂生，等 . 扶正化瘀解毒汤联合小剂量地西他滨治疗骨髓增生异常综合征临床观察 [J]. 河北中医， 2018 ， 40 ( 8 )： 1190 － 1195 .

刘超男，邓烨，李赛美，等 . 基于大数据偏序结构生成原理探讨“精准化中医”可行模式 [J]. 中华中医药杂志， 2016 ， 31 ( 5 )： 1778 － 1781 .

陶雨晨，陆嘉惠，周永明，等 . 骨髓增生异常综合征“虚毒并治”临床策略与科学实证 [J]. 中华中医药杂志， 2021 ， 36 ( 10 )： 5988 － 5992 .

OGURA M , KIM W S , UCHIDA T , et al . Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea [J]. Jpn J Clin Oncol ， 2021 ， 51 ( 2 )： 218 － 227 .

查看原文

Views

121

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Establishment and clinical application of the "three-stage and threedimension" diagnosis and treatment system for metabolic-associated fatty liver disease

Pathogenesis evolution and stage-based treatment of chronic atrophic gastritis based on "Liu Shi Run Zao"

Clinical research on the application of traditional Chinese medicine in malignant hematological diseases after cryoablation of local lesions

Exploring the mechanism of " inflammation-cancer transformation " in malignant tumors and strategies for prevention and treatment based on the yin-fire theory

Global impact and contribution of traditional Chinese medicine: a bibliometric analysis based on 98，746 studies∗

Related Author

HU Jiayan

LI Junxiang

MAO Tangyou

WANG Yuxi

LIN Zhengdao

YU Yitong

YANG Anqi

ZHENG Ting

Related Institution

Graduate School of Beijing University of Chinese Medicine

Dongfang Hospital, Beijing University of Chinese Medicine

Graduate School, China Academy of Chinese Medical Sciences

Xiyuan Hospital of China Academy of Chinese Medical Sciences

Dongzhimen Hospital, Beijing University of Chinese Medicine

AI问答

Postal code：100029
Tel：(010)53911857 Email：jbutcm@bucm.edu.cn
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰